Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jan 5:13:1092498.
doi: 10.3389/fimmu.2022.1092498. eCollection 2022.

Comprehensive comparative analysis of prognostic value of serum systemic inflammation biomarkers for colorectal cancer: Results from a large multicenter collaboration

Hailun Xie  1   2   3 , Guotian Ruan  1   2   3 , Lishuang Wei  4 , Heyang Zhang  1   2   3 , Yizhong Ge  1   2   3 , Qi Zhang  1   2   3 , Mengmeng Song  1   2   3 , Xi Zhang  1   2   3 , Xiaoyue Liu  1   2   3 , Shiqi Lin  1   2   3 , Ming Yang  1   2   3 , Chunlei Hu  1   2   3 , Meng Tang  1   2   3 , Li Deng  1   2   3 , Wen Hu  5 , Hanping Shi  1   2   3
Affiliations
Multicenter Study

Comprehensive comparative analysis of prognostic value of serum systemic inflammation biomarkers for colorectal cancer: Results from a large multicenter collaboration

Hailun Xie et al. Front Immunol. .

Abstract

Background: The incidence of colorectal cancer (CRC) is common and reliable biomarkers are lacking. We aimed to systematically and comprehensively compare the ability of various combinations of serum inflammatory signatures to predict the prognosis of CRC. Moreover, particular attention has been paid to the clinical feasibility of the newly developed inflammatory burden index (IBI) as a prognostic biomarker for CRC.

Methods: The discrimination capacity of the biomarkers was compared using receiver operating characteristic curves and Harrell's C-index. Kaplan-Meier curves and log-rank tests were used to compare survival differences between the groups. Cox proportional hazard regression analysis was used to determine the independent prognostic factors. Logistic regression analysis was used to assess the relationship between IBI, short-term outcomes, and malnutrition.

Results: IBI had the optimal prediction accuracy among the systemic inflammation biomarkers for predicting the prognosis of CRC. Taking IBI as a reference, none of the remaining systemic inflammation biomarkers showed a gain. Patients with high IBI had significantly worse overall survival than those with low IBI (56.7% vs. 80.2%; log-rank P<0.001). Multivariate Cox regression analysis showed that continuous IBI was an independent risk factor for the prognosis of CRC patients (hazard ratio = 1.165, 95% confidence interval [CI] = 1.043-1.302, P<0.001). High IBI was an independent risk factor for short-term outcomes (odds ratio [OR] = 1.537, 95% CI = 1.258-1.878, P<0.001), malnutrition (OR = 2.996, 95% CI = 1.471-6.103, P=0.003), and recurrence (OR = 1.744, 95% CI = 1.176-2.587, p = 0.006) in CRC patients.

Conclusions: IBI, as a reflection of systemic inflammation, is a feasible and promising biomarker for assessing the prognosis of CRC patients.

Keywords: biomarker; colorectal cancer; inflammatic burden Index; malnutrition; prognosis; systemic inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Comparison the effectiveness of systemic inflammation-related biomarkers in predicting the prognosis of CRC patients.
Figure 3
Figure 3
Kaplan-Meier curve of inflammatory burden index in CRC patients.
Figure 4
Figure 4
Kaplan-Meier curve of inflammatory burden index in CRC patients at internal validation cohorts. (A) Validation cohort A; (B) Validation cohort B.
See this image and copyright information in PMC

Comment on

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin (2022) 72(1):7–33. doi: 10.3322/caac.21708 - DOI - PubMed
    1. Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center (2022) 2(1):1–9. doi: 10.1016/j.jncc.2022.02.002 - DOI - PMC - PubMed
    1. Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol (2017) 11(1):97–119. doi: 10.1002/1878-0261.12018 - DOI - PMC - PubMed
    1. Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastroenterology (2016) 150(3):758–68.e11. doi: 10.1053/j.gastro.2016.01.001. - DOI - PubMed
    1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature (2001) 411(6835):380–4. doi: 10.1038/35077246 - DOI - PubMed

Substances